Business
Aeterna Zentaris Announces Closing of US$16.5 Million Public Offering of Common Shares and Warrants
QUÉBEC CITY, Oct. 17, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:&#...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, Oct. 17, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced the closing of its\n previously announced public offering of 6.6 million units (the\n \"Offering\") generating net proceeds of US$15.2 million, with each unit\n consisting of one common share and 0.45 of a warrant to purchase one\n common share, at a purchase price of US$2.50 per unit. Each warrant is\n exercisable for a period of five years at an exercise price of US$3.45\n per share. Roth Capital Partners, LLC, acted as the sole manager for the Offering.\n\n\nThe Company intends to use the net proceeds from the Offering to\n continue to fund its ongoing drug development activities, particularly\n for the continued development of perifosine in multiple myeloma and the\n advancement of its AEZS-108 and AEZS-130 programs, as well as for\n general corporate purposes and working capital.\n\n\nThis press release does not and shall not constitute an offer to sell or\n the solicitation of an offer to buy any of the Company's securities,\n nor shall there be any sale of the Company's securities in any state or\n jurisdiction in which such offer, solicitation or sale would be\n unlawful prior to registration or qualification under the securities\n laws of any such state or jurisdiction. \n\n\nAbout Aeterna Zentaris \n\n\nAeterna Zentaris is an oncology and endocrinology drug development\n company currently investigating treatments for various unmet medical\n needs. The Company's pipeline encompasses compounds at all stages of\n development, from drug discovery through to marketed products. For more\n information please visit www.aezsinc.com.\n\n\nForward-Looking Statements\n\n\nThis press release contains forward-looking statements made pursuant to\n the safe harbour provisions of the U.S. Securities Litigation Reform\n Act of 1995. Forward-looking statements involve known and unknown risks\n and uncertainties that could cause the Company's actual results to\n differ materially from those in the forward-looking statements. Such\n risks and uncertainties include, among others, the availability of\n funds and resources to pursue R&D projects, the successful and timely\n completion of clinical studies, the risk that safety and efficacy data\n from any of our Phase 3 trials ma...